New data presented showing minimal residual disease predicts relapse and survival in chronic lymphocytic leukemia patients

Adaptive Biotechnologies and collaborators from several academic institutions have presented data showing that MRD testing using the company’s clonoSEQ® Process at one year post-transplant can… Source link